OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>

BACKGROUND: There is no established treatment regimen for recurrent GBM. GBMs have activation of multiple signaling pathways in the tumor microenvironment, including the receptor tyrosine kinases, VEGFR, FGFR, and PDGFR. Regorafenib (REG), an oral multikinase inhibitor, inhibits these angiogenic kin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Lombardi, G, de Salvo, G, Rudà, R, Franceschi, E, Eoli, M, Faedi, M, Pace, A, Lolli, I, Rizzato, S, Germano, D, Pasqualetti, F, Farina, M, Magni, G, Bellu, L, Caccese, M, Pambuku, A, Bergo, E, Indraccolo, S, Gardiman, M, Soffietti, R, Zagonel, V
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Oral Presentations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144013/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.016
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky